The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Estrogen Promotes Growth of Human Thyroid Tumor Cells by Different Molecular Mechanisms1
Abstract
Thyroid tumors are about 3 times more frequent in females than in males. Epidemiological studies suggest that the use of estrogens may contribute to the pathogenesis of thyroid tumors. In a very recent study a direct growth stimulatory effect of 17beta-estradiol was demonstrated in FRTL-5 rat thyroid cells. In this work the presence of estrogen receptors alpha and beta in thyroid cells derived from human goiter nodules and in human thyroid carcinoma cell line HTC-TSHr was demonstrated. There was no difference between the expression levels of estrogen receptor alpha in males and females, but there was a significant increase in expression levels in response to 17beta-estradiol. Stimulation of benign and malignant thyroid cells with 17beta-estradiol resulted in an increased proliferation rate and an enhanced expression of cyclin D1 protein, which plays a key role in the regulation of G(1)/S transition in the cell cycle. In malignant tumor cells maximal cyclin D1 expression was observed after 3 h, whereas in benign cells the effect of 17beta-estradiol was delayed. ICI 182780, a pure estrogen antagonist, prevented the effects of 17beta-estradiol. In addition, 17beta-estradiol was found to modulate activation of mitogen-activated protein (MAP) kinase, whose activity is mainly regulated by growth factors in thyroid carcinoma cells. In response to 17beta-estradiol, both MAP kinase isozymes, extracellular signal-regulated protein kinases 1 and 2, were strongly phosphorylated in benign and malignant thyroid cells. Treatment of the cells with 17beta-estradiol and MAP kinase kinase 1 inhibitor, PD 098059, prevented the accumulation of cyclin D1 and estrogen-mediated mitogenesis. Our data indicate that 17beta-estradiol is a potent mitogen for benign and malignant thyroid tumor cells and that it exerts a growth-promoting effect not only by binding to nuclear estrogen receptors, but also by activation of the MAP kinase pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,103
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.
Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., & Auricchio, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00471.x · Cited by 959
Steroid Receptor Family: Structure and Functions
CARSON-JURICA, M. A., SCHRADER, W. T., & O'MALLEY, B. W. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-201 · Cited by 811
Endogenous hormones as a major factor in human cancer.
Henderson, B. E., Ross, R. K., Pike, M. C., & Casagrande, J. T. (1982) · PubMed · Cited by 602
Growth Factors in Breast Cancer
DICKSON, R. B., & LIPPMAN, M. E. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-5-559 · Cited by 388
Altucci, L., Addeo, R., Cicatiello, L., Dauvois, S., Parker, M., Truss, M., Beato, M., Sica, V., Bresciani, F., & Weisz, A. (1996) · PubMed · Cited by 343
A Population-Based Case-Control Study of Thyroid Cancer
(1987) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/79.1.1 · Cited by 342
Boonstra, J., Rijken, P., Humbel, B., Cremers, F., Verkleij, A., & en Henegouwen, P. V. B. (1995) · Cell Biology International · doi:10.1006/cbir.1995.1086 · Cited by 335
Persson, I., Yuen, J., Bergkvist, L., & Schairer, C. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960729)67:3<327::aid-ijc4>3.0.co;2-t · Cited by 334
Mechanism of estrogen activation of c-myc oncogene expression.
Dubik, D., & Shiu, R. P. C. (1992) · PubMed · Cited by 294
Weisz, A., & Rosales, R. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.17.5097 · Cited by 292
c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry
Prall, O. W. J., Rogan, E. M., Musgrove, E. A., Watts, C. K. W., & Sutherland, R. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.8.4499 · Cited by 267
Foster, J. S. (1996) · Molecular Endocrinology · doi:10.1210/me.10.5.488 · Cited by 244
Motokura, T., & Arnold, A. (1993) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(05)80334-x · Cited by 232
The Molecular and Neuroanatomical Basis for Estrogen Effects in the Central Nervous System
McEwen, B. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1790 · Cited by 226
Molecular Basis of Thyroid Cancer*
FARID, N. R., SHI, Y., & ZOU, M. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-2-202 · Cited by 226
Furlanetto, T. W., Nguyen, L. Q., & Jameson, J. L. (1999) · Endocrinology · doi:10.1210/endo.140.12.7197 · Cited by 161
Thyroid cancer among young women related to prior thyroid disease and pregnancy history
Preston‐Martin, S., Bernstein, L., Pike, M. C., Maldonado, A., & Henderson, B. E. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.36 · Cited by 135
Lobenhofer, E. K., Hüper, G., Iglehart, J. D., & Marks, J. R. (2000) · PubMed · Cited by 135
Thyrotropin May Not Be the Dominant Growth Factor in Benign and Malignant Thyroid Tumors
Derwahl, M., Broecker, M., & Kraiem, Z. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5519 · Cited by 94
Self-citationMcTiernan, A., Weiss, N. S., & Daling, J. R. (1984) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/73.3.575 · Cited by 81
Molecular basis of thyroid cancer
Farid, N. R. (1994) · Endocrine Reviews · doi:10.1210/er.15.2.202 · Cited by 71
Differential Effects of Protein Kinase A on Ras Effector Pathways
Miller, M. J., Rioux, L., Prendergast, G. V., Cannon, S., White, M. A., & Meinkoth, J. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3718 · Cited by 69
Leung, B. S., & Potter, A. H. (1987) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240340307 · Cited by 48
Kim‐Schulze, S., Lowe, W. L., & Schnaper, H. W. (1998) · Circulation · doi:10.1161/01.cir.98.5.413 · Cited by 46
Gire, V., Marshall, C. J., & Wynford‐Thomas, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202857 · Cited by 45
Musgrove, E. A., Šarčević, B., & Sutherland, R. L. (1996) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19960301)60:3<363::aid-jcb8>3.0.co;2-u · Cited by 37
Steroids, growth factors, and cell cycle controls in breast cancer
Musgrove, E. A., & Sutherland, R. L. (1991) · Cancer treatment and research · doi:10.1007/978-1-4615-3940-7_15 · Cited by 31
Protein Tyrosine Phosphorylation and Estradiol Actiona
Auricchio, F., Migliaccio, A., Castoria, G., Domenico, M. D., Bilancio, A., & Rotondi, A. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb16234.x · Cited by 25
Pathogenesis and Treatment of Multinodular Goiter
Derwahl, M., & Studer, H. (1998) · Endocrine updates · doi:10.1007/978-1-4615-4945-1_7 · Cited by 20
Self-citationDerwahl, M., Seto, P., & Rapoport, B. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-6-793 · Cited by 16
Self-citationMolecular Pathogenesis of Tumors of Thyroid Follicular Cells
Fagin, J. A. (1998) · Endocrine updates · doi:10.1007/978-1-4615-4945-1_3 · Cited by 14
Broecker, M., Hammer, J., & Derwahl, M. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00526-8 · Cited by 13
Self-citationBroecker, M., Mayr, G. W., & Derwahl, M. (1997) · Endocrinology · doi:10.1210/endo.138.9.5385 · Cited by 12
Self-citationOncogenes as clinical prognostic indicators
Sunderland, M. C., & McGuire, W. L. (1991) · Cancer treatment and research · doi:10.1007/978-1-4615-3940-7_1 · Cited by 10
Cited by
Golden, S. H., Brown, A., Cauley, J. A., Chin, M. H., Gary-Webb, T. L., Kim, C., Sosa, J. A., Sumner, A. E., & Anton, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2043 · Cited by 405
Estrogen and its role in thyroid cancer
Derwahl, M., & Nicula, D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0053 · Cited by 331
Self-citationMolecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter
Krohn, K., Führer, D., Bayer, Y., Eszlinger, M., Brauer, V., Neumann, S., Paschke, R., & Führer-Sakel, D. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0005 · Cited by 318
Vivacqua, A., Bonofiglio, D., Albanito, L., Madeo, A., Rago, V., Carpino, A., Musti, A. M., Picard, D., Andò, S., & Maggiolini, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.026344 · Cited by 280
RetractedAdiposity and risk of thyroid cancer: A systematic review and meta-analysis
Schmid, D., Ricci, C., Behrens, G., & Leitzmann, M. F. (2015) · Obesity Reviews · doi:10.1111/obr.12321 · Cited by 244
Metadata
- Authors
- Manole, D., Schildknecht, B., Gosnell, B., Adams, E., & Derwahl, M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-03-01
- Volume
- 86
- Issue
- 3
- Pages
- 1072-1077
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2003795355
- Cited by
- 258
- References
- 39
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.